secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unity Biotechnology, Inc. (—)
CIK:        0001463361
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059749
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unity Biotechnology Q1 net loss $5.8M, cash $38.3M; ASPIRE DME study on track
-----------------------------------------------------------------------------

- Net loss $5.8M for Q1 2024 vs $5.3M in Q1 2023; cash & securities $38.3M as of Mar 31, 2024.
- R&D expenses decreased to $3.7M from $5.8M due to completion of prior studies; focus on ASPIRE.
- Phase 2b ASPIRE study for UBX1325 in DME upsized to 50 patients, extended to 36 weeks; 24-week data expected Q1 2025, 36-week data Q2 2025.
- Cash runway sufficient into Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1463361/000095017024059749/0000950170-24-059749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1463361/000095017024059749/ubx-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer